Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Recruiting · NCT06677190 · Registry updated 2025-11-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, endocrine system disorder, endometrium neoplasm, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, uterine cancer, uterine disorder, vaginal cancer, vaginal disorder, vulva cancer, vulvar disease | Recruiting | Phase 2 | 2025-11-05 | NCT06677190 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Merck Sharp & Dohme LLC | 650 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |